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Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they
are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets
that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A
therapies.
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It has been known for more than a century that tumours have their
own blood supply and that, for the better part of that time, the
tumour vasculature is highly abnormal. At one time it was thought
that the tumour vasculature was actually superior to that of normal
tissues; this misconception arose because tumour vessels are often
of large size and were, therefore, more conspicuous than the
smaller, more numerous and functionally more effective blood
vessels of normal tissues. By the early 1970s, however, it was clear
that the overall blood flow tended to be significantly lower in
tumours than in normal tissues, and that tumours needed to
induce a vascular supply if they were to grow beyond minimal size.
It was also suspected that tumours induced their neovasculature by
secreting angiogenic factors, but the identity of these factors was
just beginning to be investigated. In the years that followed, much
has been learned about the molecular basis of angiogenesis and
particularly about the central importance of one angiogenic factor,
that is vascular permeability factor/vascular endothelial growth
factor (VPF/VEGF, VEGF-A). Subsequent work has elucidated the
steps and mechanisms by which VEGF-A induces the formation of
tumour blood vessels. Furthermore, recent successes with agents
that block VEGF-A or its receptors have supported Folkman’s
(1971) thesis that anti-angiogenesis can be a useful supplement to
traditional tumour therapy. However, current drugs that interfere
with VEGF-A function have not proved to be a cure-all (Jain et al,
2006). Their limited effectiveness, serious side effects and high cost
have prompted a rethinking of some of the basic issues involved in
tumour angiogenesis.
This minireview addresses several specific questions that are
relevant to these basic issues: what are tumour vessels and in what
respects do they differ from normal blood vessels? How do tumour
vessels form? Why are they abnormal? And, finally, why might an
understanding of tumour blood vessel diversity be important
clinically? Hopefully, addressing these questions will clarify some
of the mechanisms by which tumours induce their abnormal blood
vessels and lead to the development of therapies that more
effectively target them.
WHAT ARE TUMOUR BLOOD VESSELS AND HOW DO
THEY DIFFER FROM NORMAL BLOOD VESSELS?
Tumour blood vessels have often been regarded as if they were a
single entity, ‘angiogenic blood vessels’. However, it has long been
known that tumour blood vessels are heterogeneous with regard to
organisation, function and structure (Warren, 1979). Whereas the
normal vasculature is arranged in a hierarchy of evenly spaced,
well-differentiated arteries, arterioles, capillaries, venules and
veins, the tumour vasculature is unevenly distributed and chaotic.
Tumour vessels often exhibit a serpentine course, branch
irregularly and form arterio-venous shunts (Warren, 1979).
Blood flow through tumours does not follow a constant,
unidirectional path. Not all open vessels are perfused conti-
nuously, and, over a few minutes, blood flow may follow different
paths and even proceed in alternating directions through the
same vessel (Chaplin et al, 1987). Tumour blood vessels are more
abundant at the tumour–host interface than in central regions.
Also, vascular density tends to decrease as tumours grow,
leading to zones of ischaemia and ultimately necrosis as tumours
‘outgrow their blood supply’ (Peterson, 1991). Finally, tumour
blood vessels are structurally abnormal. On the basis of
their anatomic and functional properties, we have recently
classified tumour blood vessels into at least six distinct types.
These differ from each other, and, with the possible exception of
tumour capillaries, differ from the vessels found in normal tissues
(Table 1, Figure 1).
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Tumour angiogenesis is a relatively crude process that results from
the unbalanced secretion of a small subset of cytokines,
particularly VEGF-A (Dvorak, 2003, 2007; Nagy et al, 2007).
Recent studies with adenoviral vectors expressing VEGF-A
164
(Ad-VEGF-A
164) have contributed importantly to our under-
standing of the mechanisms by which tumours generate new
blood vessels. When injected into the tissues of immunodeficient
mice, Ad-VEGF-A
164 induces the formation of each of the different
types of tumour blood vessels listed in Table 1 and Figure 1. Similar
to tumour vessels, which show only limited tissue specificity,
the surrogate blood vessels induced by Ad-VEGF-A
164 are largely
independent of the tissue in which they arise; similar vessel types
form with similar kinetics in a wide variety of normal mouse and rat
tissues, including skin, subcutis, fat, skeletal and heart muscle, and
brain (Pettersson et al, 2000; Stiver et al, 2004). The first type of
new blood vessel to form in response to Ad-VEGF-A
164 has a
characteristic morphology and has been given the name ‘mother
vessel’ (MV) (Pettersson et al, 2000). However, similar MV-like
blood vessels are also induced by polymers containing VEGF-A
164
or basic fibroblast growth factor (Cao et al, 1998) and by tumours
expressing VEGF-A or basic fibroblast growth factor and platelet-
derived growth factor-BB (Paku and Paweletz, 1991; Bjorndahl et al,
2005; Nagy et al, 2007; Nissen et al, 2007). The other types of
angiogenic vessels evolve from MVs and thus may be properly
regarded as ‘daughter’ vessels (Figure 1) (Pettersson et al, 2000;
Dvorak, 2003; Nagy et al, 2007). In addition to angiogenesis,
tumours and Ad-VEGF-A
164 induce abnormal arteriogenesis and
venogenesis, thereby generating large vessels that feed and drain the
angiogenic vascular bed (Figure 2). Here we summarise what is
known about each of these vessel types and how they form.
MOTHER VESSELS
Mother vessels are highly permeable sinusoids that begin to
develop from pre-existing venules and, to a lesser extent, from
Table 1 Classification of tumour blood vessels
a
MV Greatly enlarged, tortuous, thin-walled,
pericyte-poor hyperpermeable sinusoids
Capillaries Similar to normal capillaries
GMP Tangles of tiny vessels immersed in a complex
mixture of irregularly ordered pericytes and
extensive multilayered basement membrane
VM Large vessels with an irregular coat of smooth muscle cells
FA and
DV
Greatly enlarged, tortuous smooth
muscle-cell-coated vessels that supply and
drain the complex of angiogenic blood vessels
DV¼draining veins; FA¼feeder arteries; GMP¼glomeruloid microvascular
proliferations; MV¼mother vessels; VM¼vascular malformations. MV, capillaries,
GMP and VM result from angiogenesis; FA and DV result, respectively, from
arteriogenesis and venogenesis.
aIn addition, red blood-cell-filled spaces lined by
tumour cells rather than by vascular endothelium have been described in some
tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’
(Folberg et al, 2000).
Precursor venule
Endothelial cell
Pericyte
Pericyte Bridged mother
(3–10 days)
Capillaries
(days–weeks)
Apoptosis
Glomeruloid microvascular
proliferations (GMP)
(1–4 weeks)
Vascular malformations
(1 week to >1 year)
Basement
membrane
degradation
Mother
(1–5 days)
Basement membrane
Smooth
muscle
cell
Figure 1 Schematic diagram of the angiogenic response induced by Ad-VEGF-A
164. Modified from Pettersson et al (2000).
Figure 2 Vascular patterns induced by Ad-VEGF-A
164 (A, B) and by MOT, a mouse ovarian tumour (C). (A, B) FA and DV (black arrows) at 27 and
59 days after s.c. injection of 10
8 PFU of Ad-VEGF-A
164. Most angiogenic vessels except for VMs (yellow arrows) have resolved. (C) Mouse ovarian tumour
10 days after s.c. implantation. Black arrows indicate some FA and DV; T, tumour.
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into mouse tissues. Mother vessel formation involves a
three-step process of basement membrane degradation, pericyte
detachment and extensive enlargement. Basement membrane
degradation is an essential early step, because basement mem-
branes are non-compliant (non-elastic) structures that do not
allow microvessels to expand their cross-sectional area by more
than B30% (Swayne et al, 1989), that is, far less than the three- to
five-fold enlargement characteristic of MVs. We have recently
shown that venular basement membrane degradation is mediated
by an increased expression of pericyte cathepsins, coupled with a
decreased expression of cysteine protease inhibitors by both
pericytes and endothelial cells (unpublished data). This upsetting
of the local cathepsin–cysteine protease inhibitor balance leads
to basement membrane degradation and detachment of
pericytes, thus removing the constraints that normally limit
microvascular size.
Rapid vascular enlargement also requires an increase in plasma
membrane. This is provided, at least in part, by vesiculo-vacuolar
organelles, which are clusters of hundreds of interconnected
vesicles and vacuoles contained within the cytoplasm of normal
venular endothelial cells. They have an important role in the
transport of macromolecules across venules in the vascular
hyperpermeability induced by VEGF-A, histamine, etc. (Dvorak
et al, 1996; Nagy et al, 2008). Vesiculo-vacuolar organelles also
provide abundant intracellular membrane stores that amount to
more than twice that of the endothelial cell plasma membrane. As
MVs develop, venular endothelial cells become thin and vesiculo-
vacuolar organelles decrease in number and complexity because
they contribute their membranes to the greatly expanded plasma
membrane.
DAUGHTER VESSELS: CAPILLARIES, GLOMERULOID
MICROVASCULAR PROLIFERATIONS AND
VASCULAR MALFORMATIONS
Mother vessels form and are maintained only as long as high
concentrations of VEGF-A are present. Their thin walls, sluggish
blood flow and a lack of pericyte and basement membrane support
make them susceptible to thrombosis or collapse. Thus, they are
transitional structures, present only for a limited time, and evolve
into one or another type of stable daughter vessel (Table 1,
Figure 1).
CAPILLARIES
One mechanism by which MVs evolve into capillaries involves
intraluminal bridging, a process that was originally discovered in
tumour vessels (Nagy et al, 1995), but which has since been found
to occur in the angiogenesis induced by Ad-VEGF-A
164 (Pettersson
et al, 2000) and healing wounds (Ren et al, 2002), and after chronic
vascular dilatation (Egginton et al, 2001). Endothelial cells extend
cytoplasmic processes into and across MV lumens, forming
transluminal bridges that divide blood flow into multiple
smaller-sized channels. Subsequently, these smaller channels
separate from each other to form individual, capillary-sized vessels
that are, as far as is known, normal in structure and are not
hyperpermeable.
GMPs
Glomeruloid microvascular proliferations (GMPs) are found not
only in a wide variety of VEGF-A-expressing human tumours,
particularly glioblastoma multiforme, but also in cancers of the
stomach and breast, where they are associated with an unfavour-
able prognosis (Pettersson et al, 2000; Sundberg et al, 2001;
Straume et al, 2002). Glomeruloid microvascular proliferations are
hyperpermeable, but, because they are poorly perfused, account
for relatively little plasma extravasation. They develop from the
proliferation of large, poorly differentiated CD31- and VEGFR-2-
positive cells, which divide MV lumens into much smaller channels
(Pettersson et al, 2000; Sundberg et al, 2001). Glomeruloid
microvascular proliferations subsequently acquire pericytes and
deposit extensive layers of abnormal basement membrane. Similar
to MVs, GMPs require exogenous VEGF-A
164 for continued
formation and maintenance.
VASCULAR MALFORMATIONS
Other MVs evolve into vascular malformation (VM) by retaining
their large size and acquiring a smooth muscle-cell coating.
Vascular malformations are readily distinguished from normal
arteries and veins by their inappropriately large size (for their
location) and by their thinner and often asymmetric muscular
coat. Vessels of this description closely resemble the non-
malignant VMs that occur, for example, in the skin, brain, etc.
(McKee, 1996). Vascular malformations are not permeable to
plasma proteins. Moreover, unlike MVs and GMPs, VMs persist
indefinitely in a low VEGF-A environment, although it is quite
possible that their lining endothelium is maintained by VEGF-A
secreted by their smooth muscle-cell coat.
FEEDER ARTERIES AND DRAINING VEINS
In addition to inducing angiogenesis, tumours and Ad-VEGF-A
164
also stimulate abnormal arteriogenesis and venogenesis, leading to
the formation of the large, often tortuous blood vessels that supply
and drain the tumour microvasculature (Figure 2). These vessels
have been little investigated. They are generally larger than VMs
and acquire structural properties that are intermediate between
arteries and veins. Similar to VMs, they persist indefinitely in a low
VEGF-A environment.
WHY ARE TUMOUR VESSELS ABNORMAL?
Tumours initiate new blood vessel formation by the local,
unbalanced overexpression of VEGF-A. As was noted more than
20 years ago, tumour angiogenesis shares many analogies with
wound healing (Dvorak, 1986). Thus, at one level, tumours can be
regarded as ‘wounds that do not heal’. Among the similarities are
high levels of local VEGF-A expression, generation of character-
istic MVs and generation of capillaries that result from intralum-
inal bridging of MVs. Of course, there are also some notable
differences. One is that, as wounds heal, VEGF-A overexpression
ceases. This is because the ischaemic stimulus upregulating the
VEGF-A expression in healing wounds diminishes as new blood
vessels form and restore local oxygen concentrations. By contrast,
tumours continue to overexpress VEGF-A unabated, because, in
tumour cells, the VEGF-A expression is driven not only by
ischaemia but also by oncogenes, loss of tumour suppressor genes,
hormones, etc. (Dvorak, 2003).
However, why does VEGF-A generate the abnormal blood
vessels characteristic of tumours and healing wounds? At least
three factors appear to be important: the total amount of VEGF-A
present locally, the different VEGF-A isoforms that are expressed
and the distribution of VEGF-A relative to target blood vessels. In
tumours, healing wounds, and in the Ad-VEGF-A
164 model,
normal blood microvessels are bathed in high concentrations of
VEGF-A, and the concentrations present locally seem to be of
critical importance in determining the character of the new blood
vessels that form. Intramuscular injection of cloned myoblasts that
secrete low amounts of VEGF-A is reported to generate non-leaky,
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amounts of VEGF-A induce typical MVs (Ozawa et al, 2004).
Also, in a model of retinal prematurity, an increased VEGF-A
caused endothelial cleavage planes to orient laterally, rather than
longitudinally, leading to the formation of enlarged vessels
(Hartnett et al, 2008).
Expression of different VEGF-A isoforms is also important
in determining neovascular structure. The major VEGF-A isoforms
(human 189, 165 and 121, all one amino acid shorter in mice)
are generated by the alternative splicing of a single gene (Ferrara
and Keyt, 1997). These isoforms generally exhibit comparable
growth factor and permeability-enhancing activities. All bind
the major VEGF-A receptors (VEGFR-2/Flk and VEGFR-1/Flt),
and all except VEGF-A
120/1 bind to a third receptor,
neuropilin. However, several VEGF-A isoforms differ strik-
ingly in their capacities to bind heparin, and cell surface and
matrix heparans (Ferrara and Keyt, 1997). VEGF-A
120/1 lacks
heparan-binding sites altogether and diffuses freely in tissues.
VEGF-A
188/9 binds strongly to cell- and matrix-associated
heparans and, at least until some threshold is exceeded, is
confined locally. VEGF-A
164/5 has intermediate heparin-
binding, and therefore diffusion, properties.
These differences in the cell and matrix-binding capacities of the
different VEGF-A isoforms have important consequences for
vascular patterning. Mice engineered to express only VEGF-A
120
develop to term but generate a capillary network with larger-sized
vessels and fewer branch points (Ruhrberg et al, 2002). Similarly,
tumour cells expressing only VEGF-A
120 form small tumours with
numerous, large peripheral blood vessels (presumably MV), but
with few, small intratumour vessels (Grunstein et al, 2000; Tozer
et al, 2008). Similar large, MV-like vessels can be generated by still
smaller VEGF-As that result from matrix metalloprotease cleavage
(Lee et al, 2005). The abnormal vascular pattern induced by
VEGF-A
120 has been attributed to its inability to bind to matrix
and, therefore, to form the steep VEGF-A gradients that are
thought to be necessary for generating normal blood vessels.
Recent work has shown that growing capillaries are comprised of
two types of endothelial cells: non-dividing ‘tip’ cells at the leading
edge that extend filopodia and sprouts in response to VEGF-A
gradients and ‘stalk’ cells that follow behind, divide and exhibit
reduced filopodia and sprouting because of signalling through the
Notch/delta 4 axis (Hellstrom et al, 2007). Thus, the shallow
gradient generated by VEGF-A
120 is thought to reduce the polarity
of tip cells and to increase their proliferation rate, causing them to
form large vessels with reduced branching.
In contrast, mice expressing only VEGF-A
188 are reported to
develop high vascular density and disorganized patterning with
lining endothelial cells that exhibit increased, multidirectional
filopodia (Ruhrberg et al, 2002). Tumour cells expressing only
VEGF-A
188 formed small tumours with numerous intratumour
blood vessels and few large peripheral vessels (Grunstein et al,
2000). This pattern is understandable, in that VEGF-A
188 is largely
cell-bound and, therefore, can induce new blood vessels only in its
immediate vicinity. Recently, fibrosarcoma cells overexpressing
VEGF-A
188 alone were found to generate better differentiated,
narrower and pericyte-coated vessels with reduced hyperperme-
ability and greater resistance to vascular disrupting agents (Tozer
et al, 2008).
Taken together, VEGF-A
120 can be regarded as a long-range
chemoattractant, involved in the initiation of vascular patterning,
whereas the longer VEGF-As are critical for establishing the
intricate, fine-patterning vessel architecture found in normal
tissues. Matrix-bound and nontethered VEGF(s) clearly ‘provide
different signalling outcomes, even though they act through the
same cell surface receptor (VEGFR2)’ (Lee et al, 2005). In contrast,
VEGF-A
164/5, the isoform most commonly expressed by tumour
cells, shares properties of both the 120/1 and 188/9 isoforms.
Tumour cells overexpressing VEGF-A
164 form large tumour
masses with both abundant peripheral and internal blood vessels,
that is, a vasculature typical of human tumours as well as of that
generated in normal mouse tissues by Ad-VEGF-A
164.
Finally, tortuosity is a property frequently exhibited by MV, VM,
feeder arteries and draining veins. Tortuosity has generally been
attributed to a restriction on lengthening, which is imposed by vessel
anchoring at fixed points upstream and downstream. As a result,
growing tumour vessels cannot extend linearly and so they coil.
WHY MIGHT AN UNDERSTANDING OF TUMOUR
BLOOD VESSEL DIVERSITY BE IMPORTANT
CLINICALLY?
Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its
receptors have provided proof of principle that anti-angiogenesis
can be a useful adjunct to tumour therapy (Jain et al, 2006).
However, these approaches have not been curative and are not
likely to be so for at least two reasons. First, they exert their effect
only within a narrow therapeutic window in which their inhibitory
effects on angiogenesis do not cause excessive toxicity; it has
become apparent in recent years that normal blood vessels, and
also the central nervous system, require VEGF-A for maintenance
and are compromised when circulating VEGF-A falls below
threshold levels (Carmeliet, 2003). Second, it is likely that
approaches targeting VEGF/VEGFR damage only a subset of
tumour blood vessels. MV and GMP are likely to be susceptible,
but daughter blood vessels such as capillaries and VMs are not, nor
are the feeder arteries and draining veins that result not from
angiogenesis but from arteriogenesis and venogenesis. Unlike MV
and GMP, these last vessels have acquired a complete and often
multilayered pericyte or smooth muscle-cell coat, and lose
detectable VEGFR-2 expression (unpublished data). As a result,
they have lost dependency on exogenous VEGF-A and can survive
indefinitely in a low VEGF-A environment. It is not surprising,
therefore, that anti-VEGF/VEGFR approaches have effectively
treated mouse tumours at early stages of their development, but
have proved to be less successful in treating established mouse
tumours that contain large numbers of more mature, smooth
muscle-cell-coated blood vessels (Bergers et al, 2003). The same
reasoning is likely to apply to human cancers. Human tumours are
typically present for months or years before they are detected; as a
result, MV and GMP are likely to account for only a small fraction
of the total tumour vasculature.
CONCLUSIONS
Tumours induce their vasculature through the unbalanced, local
overexpression of a small number of growth factors, particularly
VEGF-A. Tumour neovascularization thus differs significantly
from the sprouting angiogenesis of normal vascular development,
a process that is as yet not well understood, but that results, at least
in part, from tightly regulated VEGF-A gradients and the balanced
expression of many other growth factors and inhibitors. Tumours
generate at least six distinct types of new blood vessels that differ
from each other, and from the normal vasculature, with respect to
organisation, structure and function. This classification has
potential clinical and therapeutic significance. Current anti-
VEGF/VEGFR approaches more likely target only a subset of
angiogenic tumour blood vessels, that is, MV and GMP, that are
dependent on exogenous VEGF-A. By contrast, the mature, smooth
muscle-cell-coated daughter blood vessels, as well as the large
feeder arteries and draining veins that result from arteriogenesis
and venogenesis, are unlikely to be targeted, as they have lost
VEGF-A dependence. Feeder arteries and draining veins would
seem to be particularly valuable targets, because they supply and
drain all of the smaller, angiogenic vessels enclosed within the
tumour mass. Finding drugable targets on these blood vessels will
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proteomic revolution should make it possible to find such targets,
especially because (as success with anti-VEGF/VEGFR drugs has
shown) differences between tumour and normal blood vessels need
not be absolute for therapy to be effective.
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